Haleon PLC Sponsored ADR stock kpis
Want to see HLN full AI Analyst Report?
Revenue by Segment
In Q2 2026, Haleon PLC Sponsored ADR reported revenue by segment of £906.00M (Oral Health), £435.00M (VMS), £669.00M (Pain Relief), £351.00M (Respiratory Health) and £251.00M (Digestive Health & Other).
Shows how revenue is distributed across different business units, highlighting which areas are driving growth and which may need strategic adjustments.
Haleon PLC's Oral Health segment shows consistent growth, peaking in early 2024, indicating strong consumer demand. VMS remains stable with slight fluctuations, suggesting steady market presence. Pain Relief and Respiratory Health exhibit seasonal patterns, with notable peaks in the first quarter, potentially driven by increased consumer needs during colder months. Digestive Health & Other faces a declining trend in late 2024, which could signal shifting consumer preferences or competitive pressures. Without earnings call insights, these trends highlight the importance of strategic focus on Oral Health and addressing challenges in Digestive Health.
HLN Revenue by Segment
| Period | Oral Health | VMS | Pain Relief | Respiratory Health | Digestive Health & Other |
|---|---|---|---|---|---|
| Q2 2026Jun 30, 2026 | £906.00M | £435.00M | £669.00M | £351.00M | £251.00M |
| Q1 2026Mar 31, 2026 | £932.00M | £414.00M | £654.00M | £499.00M | £239.00M |
| Q4 2025Dec 31, 2025 | £866.00M | £430.00M | £631.00M | £470.00M | £256.00M |
| Q3 2025Sep 30, 2025 | £867.00M | £422.00M | £647.00M | £510.00M | £240.00M |
| Q2 2025Jun 30, 2025 | £848.00M | £417.00M | £625.00M | £368.00M | £237.00M |
| Q1 2025Mar 31, 2025 | £880.00M | £416.00M | £661.00M | £525.00M | £254.00M |
| Q4 2024Dec 31, 2024 | £819.00M | £432.00M | £633.00M | £433.00M | £442.00M |
| Q3 2024Sep 30, 2024 | £810.00M | £407.00M | £628.00M | £456.00M | £479.00M |
| Q2 2024Jun 30, 2024 | £829.00M | £435.00M | £641.00M | £318.00M | £552.00M |
| Q1 2024Mar 31, 2024 | £854.00M | £422.00M | £662.00M | £470.00M | £511.00M |
| Q4 2023Dec 31, 2023 | £757.00M | £414.00M | £611.00M | £458.00M | £526.00M |
| Q3 2023Sep 30, 2023 | £790.00M | £410.00M | £636.00M | £439.00M | £523.00M |
| Q2 2023Jun 30, 2023 | £778.00M | £411.00M | £681.00M | £329.00M | £553.00M |
| Q1 2023Mar 31, 2023 | £811.00M | £405.00M | £724.00M | £510.00M | £536.00M |
| Q4 2022Dec 31, 2022 | £732.00M | £422.00M | £655.00M | £439.00M | £530.00M |
| Q3 2022Sep 30, 2022 | £787.00M | £437.00M | £648.00M | £457.00M | £563.00M |
| Q2 2022Jun 30, 2022 | £697.00M | £411.00M | £613.00M | £316.00M | £524.00M |
| Q1 2022Mar 31, 2022 | £741.00M | £405.00M | £635.00M | £367.00M | £479.00M |

